NFL widows struggled to care for ex-players with CTE. They say a new study minimizes their pain
BOSTON (AP) — Dozens of widows and other caregivers for former NFL players diagnosed with CTE say a published study is insulting and dismissive of their experience living with the degenerative brain disease that has been linked to concussions and other repeated head trauma common in contact sports like football.
An open letter signed by the players' wives, siblings and children says the study published in the May 6 issue of Frontiers in Psychology suggests their struggles caring for loved ones was due to 'media hype' about chronic traumatic encephalopathy, rather than the disease itself. The implication that 'caregiver concerns are 'inevitable' due to 'publicity' is callous, patronizing, and offensive,' they said.
'The burden we experienced did not happen because we are women unable to differentiate between our lived experience and stories from TV or newspaper reports,' they wrote in the letter. 'Our loved ones were giants in life, CTE robbed them of their futures, and robbed us of our futures with them. Please don't also rob us of our dignity.'
The pushback was led by Dr. Eleanor Perfetto, herself a medical researcher and the widow of former Steelers and Chargers end Ralph Wenzel, who developed dementia and paranoia and lost his ability to speak, walk and eat. He was first diagnosed with cognitive impairment in 1999 — six years before Pittsburgh center Mike Webster's CTE diagnosis brought the disease into the mainstream media.
'My own experience, it just gave a name to what I witnessed every day. It didn't put it in my head,' Perfetto said in an interview with The Associated Press. 'It gave it a name. It didn't change the symptoms.'
The study published last month asked 172 caregivers for current and former professional football players 'whether they believed their partner had 'CTE.'' Noting that all of the respondents were women, Perfetto questioned why their experiences would be minimized.
'Women run into that every day,' she said. 'I don't think that's the only factor. I think the motivation is to make it seem like this isn't a real issue. It's not a real disease. It's something that people glommed on to because they heard about it in the media.'
Hopes for study 'quickly turned to disappointment'
The letter was posted online on Monday under the headline, 'NFL Caregivers to Harvard Football Player Health Study: Stop Insulting Us!' It had more than 30 signatures, including family of Hall of Famers Nick Buoniconti and Louis Creekmur.
It praises the study for examining the fallout on loved ones who weathered the violent mood swings, dementia and depression that can come with the disease. The letter says the study gets it wrong by including what it considers unsupported speculation, such as: 'Despite being an autopsy-based diagnosis, mainstream media presentations and high-profile cases related to those diagnosed postmortem with CTE may have raised concerns among living players about CTE.'
The letter said these are 'insulting conclusions that were not backed by study evidence.'
'Rather than exploring the lived experiences of partners of former athletes, they instead implied the partners' anxiety was caused by watching the news ... as if the media is to blame for the severe brain atrophy caused by CTE in our loved ones,' they wrote.
Study authors Rachel Grashow and Alicia Whittington said in a statement provided to the AP that the goal of their research is 'to support NFL families, especially those caring for affected players or grieving for lost loved ones.'
'We regret if any of our work suggested otherwise,' they said. 'Our intent was not to minimize CTE — a disease that is far too real — but to point out that heightened attention to this condition can intensify existing concerns, and that symptoms attributed to CTE may, in some cases, stem from other treatable conditions that also deserve recognition and care.'
But Perfetto feared the study was part of a trend to downplay or even deny the risks of playing football. After years of denials, the NFL acknowledged in 2016 a link between football and CTE and eventually agreed to a settlement covering 20,000 retired players that provided up to $4 million for those who died with the disease. (Because it requires an examination of the brain tissue, CTE currently can only be diagnosed posthumously.)
'Why would a researcher jump to 'the media' when trying to draw conclusions out of their data, when they didn't collect any information about the media,' Perfetto told the AP. 'To me, as a researcher, you draw the implications from the results and you try to think of, practically, 'Why you come to these conclusions? Why would you find these results?' Well, how convenient is it to say that it was the media, and it takes the NFL off the hook?'
'By players, for players'
The caregivers study is under the umbrella of the Football Players Health Study at Harvard University, a multifaceted effort 'working on prevention, diagnostics, and treatment strategies for the most common and severe conditions affecting professional football players.' Although it is funded by the NFL Players Association, neither the union nor the league has any influence on the results or conclusions, the website says.
'The Football Players Health Study does not receive funding from the NFL and does not share any data with the NFL,' a spokesperson said.
Previous research — involving a total of more than 4,700 ex-players — is on topics ranging from sleep problems to arthritis. But much of it has focused on brain injuries and CTE, which has been linked to contact sports, military combat and other activities that can involve repetitive head trauma.
When he died with advanced CTE in 2012 at age 69, Wenzel could no longer recognize Perfetto and needed help with everyday tasks like getting dressed or getting out of bed — an added problem because he was a foot taller and 100 pounds heavier than she is. 'When he died, his brain had atrophied to 910 grams, about the size of the brain of a 1-year-old child,' the letter said.
Former Auburn and San Diego Chargers running back Lionel 'Little Train' James, who set the NFL record for all-purpose yards in 1985, was diagnosed with dementia at 55 and CTE after he died at 59.
'Treatable conditions were not the reason Lionel went from being a loving husband and father to someone so easily agitated that his wife and children had to regularly restrain him from becoming violent after dodging thrown objects,' the letter said. 'They were not likely to be the driving force behind his treatment-resistant depression, which contributed to alcoholism, multiple stays in alcohol rehabilitation treatment centers, arrests, suicidal ideation, and ultimately, his commitment to a mental institution.'
Kesha James told the AP that she would disable the car to keep her husband from driving drunk. She said she had never spoken of her struggles but chose to tell her story now to remove the stigma associated with the players' late-in-life behavior — and the real-life struggles of their caregivers.
'I have videos that people probably would not believe,' James said. 'And I'll be honest with you: It is nothing that I'm proud of. For the last three years I've been embarrassed. I'm just going public now because I do want to help bring awareness to this — without bringing any shame to me and my kids — but just raise the awareness so that no other family can experience what I did.'
___
AP NFL: https://apnews.com/hub/NFL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
39 minutes ago
- Forbes
Connected Minds: Preparing For The Cognitive Gig Economy
Alex Lazovsky is a General Partner at Palo Alto Growth Capital, a VC firm based in Palo Alto, California—the heart of Silicon Valley. Imagine a future freelancer leasing out a slice of their own mind to a multinational corporation for an hour. In this speculative future, neural implants could allow human brains to plug into a shared 'neural cloud' on demand. Brainpower becomes a tradable resource—cognitive gig workers for hire. It sounds like science fiction, yet rapid advances in neurotechnology and big investments in brain-computer interfaces (BCIs) could someday bring that vision closer to reality. To understand how these advancements could affect businesses and investors, let's take a closer look at the existing technology and where it may be heading. Neurotech startups are already blurring the line between man and machine. Neuralink recently raised over $600 million in a funding round, catapulting its valuation to about $9 billion. This investor enthusiasm reflects the 'convergence of neuroscience and AI' and the belief that it could redefine how humans interact with technology. Neuralink demonstrated a human patient controlling a cursor and even browsing the internet using only their thoughts—early evidence of the transformative potential of high-bandwidth brain implants. Neuralink is not alone. Synchron, an Australian-American firm, has developed a less invasive implant that can be fed into the brain's blood vessels via the jugular vein, avoiding open brain surgery. Meanwhile, Precision Neuroscience raised over $100 million to develop an implant enabling users to control devices with thought. Venture capital is flooding into neurotech—total funding topped $2.3 billion in 2024, a more than threefold increase from just two years prior. From medical device firms to Big Tech, many investors see the brain as the next big platform. These efforts focus initially on healing—giving paralyzed patients new means to communicate or control prosthetics. But their long-term implications could reach further. Futurist Ray Kurzweil predicts that by the early 2030s, we may be able to network the human neocortex to the cloud over high-bandwidth connections. Companies like Neuralink, Paradromics and Blackrock Neurotech are already working on the technical substrate—micron-scale electrode threads and wireless interfaces—that might one day support a neural internet. Early research offers intriguing hints. In one experiment, neuroscientists connected three people's brains so they could jointly play a Tetris-like game via brain-to-brain communication. The system, dubbed BrainNet, showed that multiple minds can collaborate through a direct neural link, even across the internet. 'Our results raise the possibility of future brain-to-brain interfaces that enable cooperative problem-solving by humans using a 'social network' of connected brains,' the team noted. If human brains become nodes on a neural network, a new marketplace may emerge around cognitive capacity on demand. Just as cloud computing turned computing power into a utility, a 'cognitive gig economy' could turn mental work into a cloud service. Individuals might rent out spare brain bandwidth in exchange for payment, performing data analysis, pattern recognition or creative brainstorming via direct neural link. A company of the future might hire 1,000 connected minds for an hour to crowdsource a tough research problem—not by convening a meeting but by literally tapping into distributed human brains through the neural cloud. Such scenarios sound surreal, yet they extrapolate from trends already in motion. Automation and AI are transforming traditional jobs, but paradoxically, human intelligence may become a commodity itself—outsourced, fractional and ubiquitous. Knowledge workers could one day freelance their neurons, akin to Uber drivers lending their cars or time. A 'Brain-as-a-Service' industry might arise, with exchanges or platforms matching those who need cognitive help with those willing to provide it via neural link. For all its promise, this cognitive gig economy raises profound ethical and societal questions. If your brain is connected to the cloud, who safeguards your mental privacy? Brain data can reveal deeply personal information—emotions, memories, even subconscious biases. Questions of cognitive liberty loom large: Would people feel pressured to get brain implants to compete in the future job market? Could employers favor workers who can literally 'multitask' with an AI coprocessor in their heads? There's also the risk of neuro-exploitation. In a world where disadvantaged individuals might rent out their mental processing to make ends meet, new forms of inequality could emerge. The cognitive gig economy might empower people to earn money with their minds, but it could also commoditize human cognition, treating thoughts as labor units. If the 'main products of the 21st-century economy' indeed become 'bodies, brains and minds,' as Yuval Noah Harari suggests, society must grapple with how to value and protect those minds in the marketplace. What steam power and electricity were to past centuries, neural interfaces might be to this one—a general-purpose technology that could transform economies and lives. For forward-looking investors and executives, I recommend keeping a close eye on your head because it may also be your next capital asset. If the next era becomes one of connected minds, those who can balance bold innovation with human-centered ethics might shape a future where brainpower for hire could truly benefit humanity. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?


CBS News
39 minutes ago
- CBS News
Dog on Colorado's Anschutz Medical Campus leading way on novel obsessive-compulsive disorder therapy treatment
It has become common for dogs to be used for a variety of behavioral health solutions, including those like post-traumatic stress disorder, for instance. But at the University of Colorado Anschutz Medical Campus, there is a single dog that is being used in a rather unique way: helping patients with obsessive compulsive disorder, or OCD, manage their symptoms. Cate Rush, a social work fellow who works on the campus, has had Otis the Bernese Mountain Dog since her junior year of her undergraduate studies. He's helped in her in a variety of ways throughout her adult life, and she's now using him to help her patients as well. Cate Rush with Otis CBS "I just feel like it's so special that he's able to do something that humans cannot," she said. Otis is a trained therapy dog but works with a specific set of clients. Most of the patients that come see Cate have OCD. "Therapy dogs aren't commonly used for OCD so it's been a bit of a learning experience how to use him," she said. The research on the use of dogs for OCD patients is still evolving, as is most of the research around therapy dogs in general. It's only been since the turn of the 2000s that having dogs used as aids for behavioral health solutions has become more common. But it's rare to see one that is working with OCD patients. Otis is the only dog of his kind on the medical campus in Aurora. Obsessive-compulsive disorder currently affects 2.5% of the United States population and can be treated with what is called exposure and response prevention therapy, or ERPT. It usually involves exposing patients to things that trigger their obsessive behaviors while giving them tools to help prevent them from engaging in their typical compulsions. A 2010 study by the University of Pennsylvania, cited in the National Institute of Health, showed that ERPT can significantly reduce OCD symptoms in up to 80% of patients. CBS That's where Otis comes in. He can help in a variety of ways, as a supportive and helpful sidekick to those being exposed to triggering things or situations or, in some cases, being a walking exposure therapy himself. "There are a lot of patients who might have contamination fears," Rush said, "They can use him in exposure so I've had patients touch his paws or rub his belly." "I had a patient and one of her final exposures in the IOP -- the intensive outpatient program -- was to high five Otis and that was really sweet," she added. While Otis isn't part of any official research at Anschutz just yet, his presence signals an evolving approach to behavioral health solutions. One wag at a time.
Yahoo
an hour ago
- Yahoo
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT. During the webcast, Dr. Amit Kumar, Anixa's Chairman and CEO, will conduct an introductory presentation that will cover key aspects of Anixa's business including an overview of the Company's therapeutic portfolio, its business strategy, market opportunity and near-term milestones. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. To listen to the webcast or to ask questions during the live event, please pre-register at the following link: An archived version of the webcast and presentation will be available on the Company's website, About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data